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Objectives. This prospective observational study was conducted
to examine the apparent impact of a systematic direct percutane-
ous transluminal coronary angioplasty (PTCA) strategy on mor-
tality in a series of 66 consecutive patients with acute myocardial
infarction (AMI) complicated by cardiogenic shock, and to ana-
lyze the predictors of outcome after successful direct PTCA.
Background. Previous studies have reported encouraging re-
sults with PTCA in patients with AMI complicated by cardiogenic
shock, but a biased case selection for PTCA may have heavily
influenced the observed outcomes.
Methods. All patients admitted with AMI were considered
eligible for direct PTCA, including those with the most profound
shock, and no upper age limit was used. The treatment protocol
also included stenting of the infarct-related artery for a poor or
suboptimal angiographic result after conventional PTCA.
Results. Between January 1995 and March 1997, 364 consecu-
tive patients underwent direct PTCA, and in 66 patients AMI was
complicated by cardiogenic shock. In patients with cardiogenic
shock, direct PTCA had a success rate of 94%; an optimal
angiographic result was achieved in 85%; primary stenting of the
infarct-related artery was accomplished in 47%; and the in-
hospital mortality rate was 26%. Univariate analysis showed that
patient age, chronic coronary occlusion and completeness of
revascularization were significantly related to in-hospital mortal-
ity. The mean follow-up period was 16 6 8 months. Survival rate
at 6 months was 71%. Comparison of event-free survival in
patients with a stented or nonstented infarct-related artery sug-
gests an initial and long-term benefit of primary stenting.
Conclusions. Systematic direct PTCA, including stent-
supported PTCA, can establish a Thrombolysis in Myocardial
Infarction (TIMI) grade 3 flow in the great majority of patients
presenting with AMI and early cardiogenic shock. High perfor-
mance criteria, including new devices such as coronary stents,
should be considered in randomized trials where mechanical
revascularization therapy is being tested.
(J Am Coll Cardiol 1998;31:294–300)
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Patients with cardiogenic shock account for a large proportion
of deaths from acute myocardial infarction (AMI). Since 1988,
several observational studies (1–10) have reported encourag-
ing results with percutaneous transluminal coronary angio-
plasty (PTCA) in patients with AMI complicated by cardio-
genic shock. In-hospital and long-term survival is enhanced in
patients with successful revascularization, but it is possible that
biased case selection for PTCA had a favorable effect on
survival (11). The outcomes observed may have been heavily
influenced by variations in the criteria for the diagnosis of
shock, the selection criteria for angiography and revasculariza-
tion procedures, type of treatment received (i.e., fibrinolytic
agents and mechanical support devices) and time from symp-
tom onset to treatment. Therefore, a revaluation of direct
PTCA results and of the outcome predictors in a homogeneous
sample of patients with cardiogenic shock is appropriate. In
our tertiary referral center, the systematic care for AMI
includes direct PTCA in all patients presenting with AMI. This
prospective observational study was conducted 1) to examine
the apparent impact of direct PTCA on mortality in a series of
66 consecutive patients with AMI complicated by cardiogenic
shock, and 2) to analyze the clinical, angiographic and proce-
dural predictors of outcome after successful direct PTCA.
Methods
Study patients. Between January 1995 and March 1997,
374 patients with AMI eligible for direct PTCA were admitted
to our center. Six patients, all without cardiogenic shock,
refused PTCA, and four patients with cardiogenic shock died
before they could reach the catheterization laboratory. Thus,
altogether 364 patients with AMI underwent direct PTCA, and
in 66 patients (18%) the infarction was complicated by early
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cardiogenic shock. Inclusion criteria for direct PTCA were 1)
chest pain persisting .30 min with ST segment elevation on
the electrocardiogram (ECG) $0.1 mV in two or more con-
tiguous leads; 2) admission within 6 h of symptom onset, as
well as admission between 6 and 24 h in patients with evidence
of continuing ischemia; and 3) no fibrinolytic treatment admin-
istered. Angiographic exclusion criteria for direct PTCA were
1) infarct-related artery diameter stenosis ,70%, and 2)
inability to identify the infarct-related artery. Patients with
septal or papillary muscle rupture were not considered eligible
for direct PTCA, whereas patients with prior coronary artery
surgery or the usual contraindications to thrombolytic therapy
were included, and no upper age limit was used.
Cardiogenic shock was defined as systolic blood pressure
,90 mm Hg (without inotropic or intraaortic balloon support)
that was thought to be secondary to cardiac dysfunction and
associated with signs of end-organ hypoperfusion such as cold
or diaphoretic extremities or altered mental status or anuria. A
diagnosis of cardiogenic shock was to be confirmed at cardiac
catheterization by the measurement of systolic blood pressure
,90 mm Hg and left ventricular filling pressure $20 mm Hg.
Treatment protocol. Patients were pretreated with aspirin,
and heparin (10,000 U) was administered immediately after
sheath insertion. All patients received intravenous pressor
agents or intraaortic balloon pump therapy. The decision on
whether to use intraaortic balloon pump therapy was made by
an experienced interventional cardiologist, and the intraaortic
balloon was placed in the operating room under fluoroscopic
control in nearly all cases.
Direct PTCA was always attempted whatever the coronary
anatomy, and the revascularization procedure also included
nonelective stenting of the infarct-related artery in patients
with a nonoptimal angiographic result after one or more
dilations with appropriately sized balloons. Elective stenting—
that is, stenting after an optimal angiographic result achieved
by conventional angioplasty—was allowed. Direct PTCA and
coronary stenting were accomplished with standard tech-
niques, including high pressure ($14 atm) balloon inflation to
expand the stent after deployment.
After PTCA, patients were treated with aspirin (300 mg),
ticlopidine (500 mg), intravenous heparin (adjusted to keep
the partial thromboplastin time to nearly 2 times control) and
vasopressor agents as needed.
Angiographic analysis. Quantitative coronary angiography
was performed with an automatic edge detection system
(Siemens Hicor II). Coronary flow in the infarct-related artery
before and after revascularization was graded according to
Thrombolysis in Myocardial Infarction (TIMI) study group
flow classification (12). Collateral flow before direct angio-
plasty was graded using the classification developed by Ren-
trop et al. (13). A successful revascularization procedure was
defined as a residual stenosis ,50% associated with TIMI
grade 2 or 3 flow. An optimal immediate angiographic result
was defined as a residual stenosis ,30% associated with TIMI
grade 3 flow. A suboptimal angiographic result was defined as
TIMI grade 3 flow associated with a residual stenosis .30%, or
TIMI grade 2 flow associated with a residual stenosis ,50%.
Unsuccessful PTCA was defined as TIMI grade flow ,2 at any
level of residual stenosis.
Follow-up. All patients surviving cardiogenic shock under-
went clinical follow-up after hospital discharge and were
scheduled to return for follow-up catheterization at 6 months.
Patients were seen in the outpatient clinic 1, 3 and 6 months
after discharge. After 6 months, clinical information was
obtained directly from the patient (at the outpatient clinic or
by telephone interview) or from the referring physician.
Statistics. Categoric data are presented as number (per-
cent), and continuous data as mean value 6 SD or as median
value. The Fisher exact test or chi-square test analysis was used
to compare categoric variables. A two-tailed Student t test was
used to test differences among continuous variables. Survival
curves were generated by using the Kaplan-Meier method.
Survival curves were compared by the log-rank method. Logis-
tic regression analysis was used to examine independent pre-
dictors of in-hospital death. Factors analyzed included age;
gender; time to reperfusion; infarct location; evidence of prior
myocardial infarction; presence of multivessel disease, chronic
coronary occlusion or collateral vessels; infarct-related artery
stenting; optimal or suboptimal immediate angiographic result;
intraaortic balloon counterpulsation; and completeness of
revascularization at discharge, defined as no remaining steno-
sis .50%. A p value , 0.05 was considered significant.
Statistical tests were performed by using GB-STAT system
(Dynamic Microsystems).
Results
Baseline clinical and angiographic characteristics (Table
1). There were significant differences between patients with
shock and the entire group of those without shock. The former
had a significantly higher incidence of clinical factors associ-
ated with an adverse outcome, such as greater age, female
gender, previous infarction and anterior myocardial infarction.
As expected, the incidence of multivessel disease, left anterior
descending infarct-related artery and chronic coronary occlu-
sion was higher in patients with than in those without shock.
The shock group also included four patients with acute left
main trunk occlusion. The incidence of collateral flow (Ren-
trop grade 2 or 3) to the infarct area was higher in patients
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
ECG 5 electrocardiogram, electrocardiographic
GUSTO 5 Global Utilization of Streptokinase and TPA for
Occluded Coronary Arteries (trial)
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary angioplasty
SHOCK 5 Should We Emergently Revascularize Occluded
Coronaries for Cardiovascular Shock? (trial)
TIMI 5 Thrombolysis in Myocardial Infarction
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without shock, but this difference is not significant. All patients
had shock at initial assessment or within 1 h after admission.
Procedural data (Table 2). There were no differences in
time from symptom onset to reperfusion between groups. The
median time from AMI onset to reperfusion was 3.3 h.
Direct PTCA was attempted in all patients. The direct
PTCA success rate was 94% for patients with shock and 98%
for patients without shock (p 5 0.038), and an optimal
immediate angiographic result was achieved more frequently
in the latter group (85% and 96%, respectively, p 5 0.001).
Primary PTCA failure occurred in four patients with shock. All
four patients with cardiogenic shock and failed PTCA died;
two of the four were referred for emergency surgery, and died
after coronary artery bypass grafting (CABG), and the other
two died in the catheterization laboratory during attempted
PTCA. The incidence of primary stenting of the infarct-related
artery was similar in the patients with (47%) and without
(48%) shock. Patients with cardiogenic shock needed multiple
stent implantation more frequently as a result of more severe
and diffuse disease of the infarct artery (21% vs. 15%, p 5 NS
[0.278]). Stenting was elective in 7 patients (24%) and non-
elective because of a nonoptimal result after PTCA in 22
(76%). A total of 43 stents were placed in patients with shock:
22 Gianturco-Roubin stents (Cook Inc.), 16 Palmaz-Schatz
stents (J & J Interventional Systems), and 5 Microstents
(AVE). Short stents or coiled stents were used when a difficult
negotiation could be predicted from anatomic characteristics
of the vessel. At least one stent was successfully deployed in all
cases attempted. Additional stents could not be deployed in
two patients with dissection distal to one successfully deployed
stent. PTCA of noninfarct arteries was successfully performed
in two patients with cardiogenic shock and severe (.70%
stenosis) multivessel disease, and four patients with hemody-
namically stable multivessel disease were referred for elective
CABG before discharge. Overall, 10% of patients with cardio-
genic shock needed percutaneous or surgical multivessel re-
vascularization, whereas only 2% of patients without shock had
in-hospital multivessel revascularization (p 5 0.005). Intraaor-
tic balloon pump therapy was administered in 47 patients with
(76%) and in 20 patients without (7%) shock (p , 0.001).
Nineteen patients with cardiogenic shock did not have in-
traaortic balloon placement because they had severe athero-
sclerotic disease or tortuosity of the iliac arteries and the
systolic blood pressure could be supported at .80 mm Hg by
intravenous pressor agents.
In-hospital outcome of patients with cardiogenic shock
(Tables 3 and 4). In 66 patients with cardiogenic shock the
mortality rate was 26% (17 of 66). In patients with successful
PTCA the mortality rate was 21% (13 of 62). In the group
without shock the mortality rate was 0.7% (2 of 298, p ,
0.001). In patients with successful PTCA, progressive deterio-
ration in the setting of refractory cardiogenic shock was the
most frequent cause of death (6 patients); the other causes of
death in the remaining hemodynamically stabilized patients
were respiratory failure (2 patients), fatal reinfarction (2
patients), a ruptured chronic aortic aneurysm (1 patient) and
vascular complications of intraaortic balloon pumping (2 pa-
tients died after vascular surgery). Reocclusion of the infarct-
Table 2. Procedural Characteristics in Patients With and Without
Cardiogenic Shock
With Shock
(n 5 66)
Without shock
(n 5 298)
p
Value
Time from AMI onset to
reperfusion (h)
3.6 6 1.5 3.4 6 1.7 0.520
Median time to reperfusion (h) 3.3 3.3
PTCA failure 4 (6%) 5 (2%) 0.038
PTCA success 62 (94%) 293 (98%) 0.038
Optimal angiographic result 56 (85%) 285 (96%) 0.001
Suboptimal angiographic result 6 (9%) 8 (3%) 0.014
Stenting of the IRA* 29 (47%) 140 (48%) 0.885
Multiple stent implantation* 13 (21%) 45 (15%) 0.278
Multivessel revascularization* 6 (10%) 6 (2%) 0.005
PTCA 2 (3%) 3 (1%)
CABG 4 (6%) 3 (1%)
IABP 47 (71%) 20 (7%) , 0.001
Intubation 10 (15%) 0 , 0.001
*For patients with PTCA success: n 5 62 with shock; n 5 293 without shock.
Data are presented as mean value 6 SD, median or number (%) of patients in
group. AMI 5 acute myocardial infarction; CABG 5 coronary artery bypass
graft surgery; IABP 5 intraaortic balloon counterpulsation; IRA 5 infarct-
related artery; PTCA 5 percutaneous transluminal coronary angioplasty.
Table 1. Comparison of Baseline Clinical and Angiographic
Characteristics of 364 Patients With and Without Cardiogenic Shock
Treated With Direct PTCA
With Shock
(n 5 66)
Without Shock
(n 5 298)
p
Value
Age (yr)
Mean 65 6 11 62 6 12 0.023
Range 40–82 28–89
.75 yr 15 (23%) 40 (13%) 0.056
Male 43 (65%) 239 (80%) 0.008
Diabetes mellitus 11 (17%) 38 (13%) 0.399
Prior myocardial infarction 17 (26%) 27 (9%) , 0.001
Exertional angina 15 (23%) 38 (13%) 0.038
Unstable angina 17 (26%) 99 (33%) 0.239
Systolic blood pressure (mm Hg)* 74 6 13 129 6 25 , 0.001
Infarct location
Anterior 48 (73%) 153 (51%) 0.002
Inferior 18 (27%) 137 (46%) 0.005
Lateral 0 8 (3%) 0.178
Infarct-related artery
LAD 44 (67%) 153 (51%) 0.024
RCA 17 (26%) 120 (40%) 0.027
LCx 1 (1%) 25 (9%) 0.049
Left main trunk 4 (6%) 0 , 0.001
Multivessel disease 44 (67%) 147 (49%) 0.011
Chronic occlusion 27 (41%) 26 (9%) , 0.001
Rentrop grade 2 or 3 collateral
flow
4 (6%) 38 (13%) 0.124
*Measured at cardiac catheterization. Data are presented as mean value 6
SD or number (%) of patients in group. LAD 5 left anterior descending
coronary artery; LCx 5 left circumflex coronary artery; PTCA 5 percutaneous
transluminal coronary angioplasty; RCA 5 right coronary artery.
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related artery occurred in 8 (13%) of the 62 patients with
cardiogenic shock. Two of the 62 had a fatal reinfarction
(including 1 patient with a stented infarct-related artery), and
6 patients (10%) had recurrent ischemia. Recurrent ischemia
occurred only in patients without primary stenting. Repeat
PTCA was successfully performed in all patients with recurrent
ischemia, and all but one patient with recurrent ischemia
underwent bailout stenting of the infarct-related artery. Over-
all, recurrent ischemia or reinfarction occurred more fre-
quently in patients without than in patients with a stented
infarct-related artery (21% vs. 3%, p 5 0.040).
Univariate analysis of factors associated with in-hospital
mortality in patients with cardiogenic shock and successful
PTCA (Table 4) demonstrated that age (odds ratio) [OR] 5
1.077, p 5 0.040), chronic coronary occlusion (OR 5 4.235,
p 5 0.032) and completeness of revascularization (OR 5
0.068, p 5 0.013) were significantly related to in-hospital
mortality. The mean age was 63 years among survivors and 70
years among nonsurvivors. The mortality rate of patients .75
years old was 36%. Anterior location of the current infarction
was not related to in-hospital mortality. Among patients with
inferior infarction, seven were identified as having right ven-
tricular involvement by ECG criteria. There was no difference
between the mortality rate of patients with right ventricular
infarction and that of patients without right ventricular in-
volvement (29% vs. 20%, p 5 0.682). By multivariate analysis,
no collected clinical and angiographic variable remained as an
independent predictor of in-hospital outcome.
Follow-up (Table 5). The 49 patients surviving cardiogenic
shock had a mean clinical follow-up period of 16 6 8 months.
The survival rate at 6 months was 71% (Fig. 1). During the
6-month period, there were two deaths and two nonfatal
reinfarctions. Four patients with recurrent ischemia and sig-
nificant restenosis of the infarct-related artery underwent
repeat PTCA, whereas three underwent cardiac surgery
Table 3. In-Hospital Outcome of 66 Patients With
Cardiogenic Shock
No. (%)
of Patients
Primary failure (n 5 4)
Death 4 (100%)
Successful PTCA (n 5 62) 62 (94%)
Death 13 (21%)
Refractory shock 6 (10%)
Respiratory failure 2 (3%)
Reinfarction 2 (3%)
Vascular complications 3 (5%)
Recurrent ischemia 6 (10%)
Recurrent ischemia or reinfarction 8 (13%)
Patients with stenting (n 5 29) 1 (3%)
Patients without stenting (n 5 33) 7 (21%)
Emergency repeat PTCA 6 (10%)
Overall mortality 17 (26%)
PTCA 5 percutaneous transluminal coronary angioplasty.
Table 4. Univariate Logistic Regression Analysis of Clinical, Angiographic and Procedural
Characteristics Relevant to In-Hospital Mortality of 62 Patients With Cardiogenic Shock and
Successful Direct PTCA
Survivors
(n 5 49)
Nonsurvivors
(n 5 13) OR 95% CI
p
Value
Age (yr) 63 6 11 70 6 10 1.077 1.003–1.157 0.040
Female gender 17 (35%) 4 (30%) 0.791
Time to reperfusion (h) 3.6 6 1.5 3.2 6 2.0 0.364
Anterior AMI 36 (73%) 9 (69%) 0.761
Prior infarction 11 (22%) 5 (38%) 0.247
Multivessel disease 29 (59%) 12 (92%) 0.051
Chronic occlusion 17 (35%) 9 (69%) 4.235 1.135–15.8 0.032
Rentrop grade 2 or 3 collateral flow 4 (8%) — 0.314
Stenting 23 (47%) 6 (46%) 0.960
Suboptimal result 6 (12%) — 0.327
IABP 35 (71%) 8 (62%) 0.494
Completeness of revascularization 27 (55%) 1 (8%) 0.068 0.008–0.564 0.013
Data are presented as mean value 6 SD or number (%) of patients in group. CI 5 confidence interval; OR 5 odds
ratio; other abbreviations as in Table 2.
Table 5. Six-Month Clinical and Angiographic Follow-Up of 49
In-Hospital Survivors
No. (%)
of Patients
Clinical follow-up
Death 2 (4%)
Nonfatal reinfarction 2 (4%)
Repeat PTCA 4 (8%)
Cardiac surgery 3 (6%)
NYHA functional class I or II 39 (80%)
Angiographic follow-up
Eligible for 6-month angiography 37 (76%)
Coronary angiography performed 34 (92%)
Patency 31 (91%)
Reocclusion 3 (9%)
Restenosis 10 (29%)
NYHA 5 New York Heart Association; PTCA 5 percutaneous transluminal
coronary angioplasty.
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(CABG in one, left ventricular aneurysmectomy without by-
pass grafting in one and heart transplantation in one). Eighty
percent of patients surviving cardiogenic shock were in New
York Heart Association functional class I or II at 6 months.
After 6 months, no patient had a myocardial infarction, four
patients underwent a repeat revascularization procedure and
one patient died (Fig. 2).
The 6-month angiographic follow-up rate was 92%. The
patency rate of infarct-related arteries was 91%. There were
three reocclusions of the infarct-related artery. The reocclu-
sion was asymptomatic in two patients, whereas one patient
experienced nonfatal reinfarction. Ten patients had .50%
restenosis of the infarct-related artery. The incidence of .50%
restenosis or reocclusion between hospital discharge and 6
months was 38%. The cumulative in-hospital and 6-month
incidence of significant restenosis or reocclusion of the infarct-
related artery was lower in patients with a stented infarct-
related artery than in patients who underwent conventional
PTCA alone (3 [20%] of 15 vs. 16 [67%] of 24, p 5 0.005). As
a consequence, a lower incidence of events related to resten-
osis or reocclusion of the infarct-related vessel was noted in
patients with stenting of this vessel (Fig. 3).
Discussion
Study patients. Several observational studies (1–10) have
examined the use of emergency PTCA in patients with AMI
complicated by cardiogenic shock. All of these studies reported
decreased mortality after successful reperfusion of the infarct-
related artery, but none clearly defined the criteria for the
selection of certain patients for PTCA and others for conven-
tional care, and a case selection bias may explain the favorable
results described. The investigators from the Should We
Emergently Revascularize Occluded Coronaries for Cardio-
vascular Shock? (SHOCK) registry (11) showed that 1) pa-
tients with AMI complicated by cardiogenic shock are a very
heterogeneous group, and 2) that those selected to undergo
coronary angiography had a lower mortality rate whether or
not they underwent revascularization. The results of the
SHOCK registry confirm that the selection process for emer-
gency coronary angiography is such that the most critically ill
patients are often not taken to the catheterization laboratory,
whereas aggressive care is offered more often to the patients
most likely to survive. This selection bias also applies to the
results of PTCA in the Global Utilization of Streptokinase and
TPA for Occluded Coronary Arteries (GUSTO I) trial (14),
where PTCA was performed in only 15% of patients with
shock on arrival and in only 20% of those who experienced
shock after admission to the hospital. To obviate the confound-
ing effects of selection bias on patient outcome, the ongoing
randomized SHOCK trial will determine the benefit of early
mechanical revascularization and of several new support de-
vices in different subgroups of patients with cardiogenic shock.
In the present study this selection bias did not exist, because
primary PTCA therapy was offered to all patients admitted
with AMI within 6 h from symptom onset (or longer if there
was evidence of continuing ischemia), and no upper age limit
was used. Patients with the most profound shock were in-
cluded; four patients died before they could reach the cathe-
terization laboratory, and two died at the beginning of a failed
PTCA attempt. Furthermore, patients treated with fibrinolytic
agents were excluded from the study to avoid the confounding
effects on results of previous different fibrinolytic treatments
and of the criteria adopted to select patients for rescue PTCA.
The high incidence of cardiogenic shock in our study
patients may be explained by the willingness of physicians to
refer predominantly high risk patients for direct PTCA to our
hospital because it has had a primary PTCA program since
Figure 1. Actuarial survival of 66 patients with AMI complicated by
cardiogenic shock who were treated by direct PTCA.
Figure 2. Event-free survival curve after successful PTCA for 62
patients with cardiogenic shock. Cardiac events include death, myo-
cardial infarction and any cardiac revascularization procedure.
Figure 3. Event-free survival plotted for subgroups with a stented or a
nonstented infarct-related artery. Cardiac events include death, myo-
cardial infarction and infarct-related artery revascularization proce-
dures.
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1994 and serves as a regional referral center for several
community hospitals and smaller neighboring hospitals within
a 50-mile radius, as well as for the network of mobile coronary
care units. A treatment bias with preselection of patients most
likely to survive for referral to our institution is unlikely,
because the selection process by clinicians is such that all
patients with frank or incipient shock are immediately re-
ferred, including patients with a typically poorer outcome, such
as those .75 years old or with the most profound shock.
Timing of shock. The temporal profile of cardiogenic shock
in our study is different from that of other studies. In our study
all patients had shock either on admission or within 1 h after
admission, with a median interval between symptom onset and
treatment of 3.3 h. In other studies, based on heterogeneous
population samples, the median time from AMI onset to shock
diagnosis was longer. The SHOCK registry investigators re-
ported a median time of 8 h from AMI onset to shock
diagnosis for the entire population of 251 patients registered
(11); for the subgroup of 181 patients in whom shock devel-
oped within 24 h, the median time from AMI onset to shock
diagnosis was 3.5 h (15). This registry also included patients
with ST segment depression or mechanical complications, such
as ventricular septal defect or mitral regurgitation, that could
have lengthened the median interval between AMI onset and
shock diagnosis. In the GUSTO I trial (14), which enrolled
41,021 patients with AMI, cardiogenic shock was identified in
2,972 patients (7.2%). Of the patients with shock, 89% expe-
rienced shock within 48 h of admission, most commonly in the
setting of recurrent ischemia or reinfarction, whereas only 11%
had shock on arrival. The small number of the latter patients
may be a consequence of having excluded the majority of such
patients from enrollment in clinical trials.
In our center the large majority of patients who undergo
direct angioplasty are referred with the indication for imme-
diate angiography and are directly admitted to the catheter-
ization laboratory. This explains the short median time from
symptom onset to treatment. The short delay from AMI onset
to reperfusion is likely to have a beneficial effect on results.
Procedural results. The revascularization procedure suc-
cess rate was 94%, and an optimal angiographic result (resid-
ual stenosis ,30% associated with TIMI grade 3 flow and no
dissection) was achieved in 85% of cases. These procedural
results compare favorably with the 54% to 76% success rates of
previous studies (1,9,10) of PTCA in patients with cardiogenic
shock. The improvement in equipment and techniques and the
availability of new devices, such as coronary stents, may explain
these favorable immediate angiographic outcomes. In our
study nearly half of the patients had primary stenting on the
infarct-related artery because of a suboptimal or a poor
angiographic result after dilation, and 21% of the patients had
multiple stent implantation as a consequence of severe and
diffuse disease of the infarct-related artery. Furthermore, all
patients in the GUSTO I trial, and a substantial proportion
(21% to 47%) of patients of other series (10,11,14) were
previously treated with fibrinolytic agents and the procedural
success rate in these studies could have been lowered by the
proved adverse effects of fibrinolytic agents on the PTCA
results (16).
In-hospital outcome. The overall mortality rate of 26% and
the rate of 21% for our patients with successful revasculariza-
tion compare favorably with the 36% to 61% mortality rates
from other series (1–11,14). The high rate of restoration of
TIMI grade 3 flow that was associated with successful revas-
cularization procedures may explain these differences, inas-
much as restoration of TIMI grade 3 flow is predictive of
in-hospital survival and a reduction in infarct size, whereas
TIMI grade 2 flow is associated with in-hospital outcomes
similar to those of patients with occluded infarct-related
arteries (TIMI grades 0 and 1) (17). The achievement of an
optimal immediate angiographic result in the great majority of
patients with successful recanalization may be explained by the
high number of patients who had successful infarct-related
artery stenting because of a poor or suboptimal angiographic
result after conventional PTCA. Coronary stenting in the
setting of AMI is feasible and provides better angiographic
results than those of conventional PTCA alone, and it is
associated with a good in-hospital outcome (18–20). In the
subgroup of patients with a stented infarct-related artery,
reocclusion of the artery consequent to stent thrombosis
occurred in only one patient (3%), who died of fatal reinfarc-
tion. No patient with primary stenting had recurrent ischemia,
whereas in the subgroup of patients who underwent conven-
tional PTCA alone, the in-hospital recurrent ischemia or
reinfarction rate was 21%. These results suggest a benefit of
coronary stenting in patients with AMI complicated by cardio-
genic shock as well.
Age, chronic coronary occlusion and completeness of re-
vascularization were highly associated with mortality. The
mean age was 63 years among survivors and 70 years among
nonsurvivors. The association of chronic coronary occlusion
with a higher mortality rate is not surprising, because patients
with chronic coronary occlusion included patients with the
most severe multivessel disease. Completeness of revascular-
ization was inversely related to mortality. Most patients with
complete revascularization had single-vessel disease; the small
number of patients with multivessel disease who underwent
complete revascularization makes it difficult to reach any
definite conclusion about the real benefit of complete revas-
cularization in patients with multivessel disease and cardio-
genic shock. By multivariate analysis, age and other clinical
and angiographic variables did not remain independent pre-
dictors of mortality. This observation is consistent with the
SHOCK registry report (11), and it should be noted that the
sample size analyzed may be too small to detect any statistical
significance. Despite their higher mortality rate, the results of
our study suggest that an aggressive intervention cannot be
considered a contraindication in extremely aged patients with
cardiogenic shock.
Long-term survival. There is a paucity of data concerning
long-term survival after successful PTCA in patients with
cardiogenic shock. Our long-term survival rate of 71% com-
pares favorably with those of previous studies, where it ranged
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from 45% to 54% (2,6,8,10). In the majority of survivors, major
cardiac adverse events occurred within 6 months after AMI.
Comparison of event-free survival curves of patients with a
stented and nonstented infarct-related artery suggests that the
benefit of primary stenting is maintained even through long-
term follow-up.
Conclusions. Successful early mechanical revascularization
by direct PTCA, including stent-supported PTCA, in patients
with AMI complicated by early cardiogenic shock favorably
affects the otherwise poor outcome in this patient group.
Systematic direct PTCA can establish TIMI grade 3 flow in the
great majority of patients presenting with AMI and early
cardiogenic shock. As survival is clearly linked to reperfusion
status, high performance criteria, including new devices, such
as coronary stents, should be considered in ongoing random-
ized trials where PTCA therapy is being tested.
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